Several new developments from the U.S. Food and Drug Administration (FDA) have strong implications for psychological practice.
- The FDA announced the formation of a new Digital Health Advisory Committeeopens in new window that will support the agency’s efforts to regulate rapidly developing digital health technologies. Psychological science will be well represented: The FDA appointed psychologist Jessica Jackson, PhD, chair of APA’s Mental Health Technology Advisory Committee, to serve on the new FDA committee.
- The FDA declined to approve Lykos Therapeutics’ new drug application for MDMA as a treatment for PTSD. This comes after an expert advisory committeeopens in new window raised concerns about the clinical trial design. Lykos is currently working to address the concernsopens in new window raised by the FDA.
- SleepioRxopens in new window, a digital therapeutic from Big Health, was cleared by the FDA in early Augustopens in new window as a treatment for insomnia. On September 4, the FDA also cleared DaylightRxopens in new window, a digital treatment for generalized anxiety disorder. Psychologists and other qualified health care professionals will be able to offer and order these new evidence-based tools to support their practice and improve and expand access to care for their patients.
Each month, APA’s Office of Health Care Innovation (OHCI) highlights the latest health care innovations and policies that impact psychological practice. Learn more about OHCI.
